Results 301 to 310 of about 2,266,569 (385)

Aseptic Sinusitis: A New Phenotype of Immune-Related Rhinosinusitis in the Era of Immune Checkpoint Inhibitors. [PDF]

Clin Case Rep
Yalovitser J, Nguyen K, McKenna K, Ahmed S, Orgain C.   +4 more
europepmc   +1 more source

PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1‐KDM5C‐IL6 Axis in ccRCC

Advanced Science, EarlyView.
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia, Hongru Wang, Yu Dong, Zitong Yang, Yiyang Zhou, Zhinan Xia, Qinchen Li, Liangliang Ren, Yichun Zheng, Junliang Yan, Dongmei Ma, Zhi Chen, Xingang Cui, Guixin Zhu, Cheng Zhang   +14 more
wiley   +1 more source

Immune Checkpoint Restoration as a Therapeutic Strategy to Halt Diabetes-Driven Atherosclerosis. [PDF]

Biology (Basel)
Saha D, Dutta P, Chakraborty A.
europepmc   +1 more source

Stress‐Programmed Immune Niches Fuel TNFR2+ Treg Activation and Drive Neoadjuvant Chemotherapy Resistance in Breast Cancer

Advanced Science, EarlyView.
Single‐cell sequencing reveals stress‐programmed immune states driving TNFα–TNFR2–mediated Treg activation and therapy resistance in breast cancer, while targeting this axis restores antitumor immunity. ABSTRACT The tumor microenvironment (TME) harbors diverse immune cell states that shape therapeutic outcomes in breast cancer.
Zhibo Shao, Xuliren Wang, Han Zhu, Ling Yao, Qi Zhang, Zihan Zhai, Xinyi Lv, Xinyuan Xia, Yi Zhang, Xinya Lu, Xinyi Quan, Jiawen Yang, Xinwei Li, Jieyi Dong, Zhi‐ming Shao, Ruoxi Wang, Bingqiu Xiu, Jiong Wu, Sheng Chen   +18 more
wiley   +1 more source

CXCR6⁺ T Cells Drive Immune Checkpoint Inhibitor Myocarditis. [PDF]

Circulation
Munir AZ, Gutierrez A, Krawiec CJ, Manandhar P, Shyani AC, Ma P, Gougis P, Baylis RA, Hou L, Remold-O'Donnell E, Balko JM, Salem JE, Lavine KJ, Lichtman AH, Qin J, Moslehi JJ.   +15 more
europepmc   +1 more source

Host‐Directed Antiviral Activity of SB2960 Through Selective Induction and Remodeling of Stress Granules

Advanced Science, EarlyView.
Amid the ongoing threat of emerging viral pathogens, host‐directed antivirals offer a strategy to overcome viral mutation and drug resistance. SB2960, a small‐molecule inducer of stress granules (SGs), exhibits potent broad‐spectrum antiviral activity with minimal cytotoxicity.
Wan Gi Byun, Sumin Son, JinAh Lee, Minha Lee, Meehyun Ko, Songrui Zhao, Ju Hee Kim, Kannan Vaithegi, Ji Hoon Kwon, Jung Ho Lee, Sangeun Jeon, Dawon Yi, Peng Zou, Seungtaek Kim, Seung Bum Park   +14 more
wiley   +1 more source

Incidence of Immune Checkpoint Inhibitor-Associated Renal Tubular Acidosis. [PDF]

Kidney Int Rep
Shah CV, Kim EM, Mathavan A, Mathavan A, Shah N, Ilyas M, Nguyen J, Weiner ID.   +7 more
europepmc   +1 more source

Integrated cancer cell-specific single-cell RNA-seq datasets of immune checkpoint blockade-treated patients

Mahnoor Gondal, Marcin Cieślik, Arul M. Chinnaiyan   +2 more
openalex   +1 more source

TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy

Advanced Science, EarlyView.
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng, Jiaxing Huang, Shengnan Lv, Jian Zhang, Liangliang Zhang, Huan Liu, Yan Liu, Zhen‐An Qiao, Feng Wei, Bao‐Lian Su   +9 more
wiley   +1 more source

Long-Term Toxicities of Immune Checkpoint Inhibitors. [PDF]

Drugs
Abraham PE, Johnson DB.
europepmc   +1 more source